RT Journal Article
SR Electronic
T1 Tailoring Radiation Therapy for Patients With Limited Cutaneous T Cell Lymphoma: Preliminary Clinical Experience With Subtotal Skin Electron Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1491
OP 1497
DO 10.21873/anticanres.16945
VO 44
IS 4
A1 LAUGHLIN, BRADY S.
A1 ZANILETTI, ISABELLA
A1 FOSTER, MADELINE G.
A1 LUCIDO, JOHN
A1 MANGOLD, AARON R.
A1 ROSENTHAL, ALLISON C.
A1 VAN DER WALT, CHARLES
A1 BREEN, WILLIAM
A1 LESTER, SCOTT
A1 HOPPE, BRADFORD
A1 PETERSEN, JENNIFER
A1 ARMSTRONG, MICHAEL D.
A1 BOGAN, AARON
A1 RULE, WILLIAM G.
YR 2024
UL http://ar.iiarjournals.org/content/44/4/1491.abstract
AB Background/Aim: Total skin electron beam therapy (TSEBT) is an effective treatment for managing cutaneous T-cell lymphoma (CTCL), but may result in unnecessary toxicity. With the production of a custom rolling shield holding a configurable stack of plastic slats to block uninvolved skin, we implemented a program for subtotal skin electron beam therapy (STSEBT). We report our preliminary experience with STSEBT vs. TSEBT to manage CTCL. Patients and Methods: A retrospective review of 32 CTCL patients who were treated at a single institution between February 28th, 2017, and May 25th, 2022, was completed. Of these cases, seven patients received STSEBT and 25 received TSEBT. Results: Thirty-two patients underwent a course of STSEBT or TSEBT. The median follow-up was 465 days and the median age at diagnosis was 70.8 years. Stage distribution was as follows: one (3%) IA, 16 (50%) IB, 6 (19%) IIB, two (6%) IIIA, five (16%) IVA, and two (6%) IVB. The overall response rate was 96%. For patients receiving TSEBT (n=25), three (12%), 10 (40%), and 11 (44%) had a CR, NCR, and PR, respectively. For the patients receiving STSEBT, four (57.1%), three (42.9%), and zero (0%) had a CR, NCR, and PR, respectively. There was one patient (4%) with no response. Cumulative incidence of progressive skin disease requiring additional electron therapy at three months was 21.1% [IQR=8.6, 51.5%], 36.8% [IQR=20, 68%] at six months, and 57.9% [IQR=38.5, 87.1%] at one year. Low rates of toxicities were recorded. Conclusion: This analysis demonstrated that treatment of CTCL patients with low disease burden with STSEBT results in similar overall response and time to progression compared to treatment with TSEBT.